Author

Dana Pueschl

University of PennsylvaniaORCID 0000-0002-1300-1534Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Katherine L. NathansoniD· 2 shared Susan M. DomchekiD· 2 shared Aaron J. LongworthiD· 1 shared Andrew K. GodwiniD· 1 shared Angela Lincy Prem Antony SamyiD· 1 shared Antonis C. AntoniouiD· 1 shared Anupma NayakiD· 1 shared Arjun Nair· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Katherine L. NathansonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 30, 2026

Cell-of-origin shapes tumor subtype in BRCA1-associated triple-negative breast cancer

Tatyana Lev, Angela Lincy Prem Antony Samy, Sharmila Mallya…·Devon A. Lawson

This study identifies two cell-of-origin-driven subtypes of BRCA1-associated TNBC, showing that tumor subtype depends on the cell type initiating the cancer.

DOI 10.64898/2026.09.29.755499

mousescRNA-seq

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintSep 19, 2025

Genomic profiling of young-onset gBRCA1/2 breast cancer reveals distinct genomic landscapes and therapeutic implications for PARP and CDK4/6 inhibitor selection

Mwangala P. Akamandisa, Mingyi Xia, Wilson Cheah…·Katherine L. Nathanson

This study compares genomic features of gBRCA1 and gBRCA2 breast cancers, finding distinct mutational patterns and therapeutic implications for PARP and CDK4/6 inhibitors.

1 citation

humanwhole-exome sequencing

𝕏 PostBluesky